Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression

In 2020, a risk analysis was conducted on Lurasidone, a drug approved by the FDA for the treatment of schizophrenia and bipolar depression. The study analyzed 17 out of 419 published studies from October 2010 to July 2019. The analysis found that Lurasidone had several adverse drug reactions (ADRs) not listed in the original product characteristics, including telogen effluvium (a form of hair loss), thrombocytopenia, restless leg syndrome, and hypersexuality. The study concluded that while Lurasidone is an effective treatment for bipolar depression and schizophrenia, more data is needed on the safety of the drug in a larger population.